Why Is Azenta (AZTA) Stock Down -23% Today?
Key Takeaways
- AZTA shares plunged 23.82% to close at $18.75 from the previous close of $24.61.
- Primary catalyst: Q2 fiscal 2026 earnings miss, with revenue of $145 million missing estimates of $148.75 million and non-GAAP EPS loss of $0.04 versus expected $0.11 profit.
- Secondary drivers: $149 million non-cash goodwill impairments, gross margin contraction to 42.8%, and lowered FY2026 guidance for organic revenue to -2% to +1%.
- Trading volume elevated at 964,691 shares versus average of around 900,000, indicating strong selling pressure amid healthcare sector softness.
- Move diverged negatively from broader biotech ETFs like IBB and XBI, which saw milder declines.
- Traders watching execution improvements, Multiomics transformation, and Q3 results in August.
Breaking Down AZTA's Sharp Decline
I've been keeping an eye on AZTA, the provider of sample management and multiomics solutions for the life sciences industry, and its stock took a significant hit recently. Shares plummeted 23.82% in the latest trading session, closing at $18.75 after the prior close of $24.61. From what I see, this move was triggered by disappointing Q2 fiscal 2026 results released before the market open, which exposed some execution shortfalls and softer demand than anticipated.
Digging into the Q2 Earnings
Azenta's Q2 revenue from continuing operations came in at $145 million, marking just a 1% year-over-year increase but a 3% organic decline after adjusting for foreign exchange and the UK Biocentre acquisition. This missed analyst expectations of $148.75 million. Non-GAAP diluted EPS showed a loss of $0.04, well below the forecasted $0.11 profit and a reversal from the prior year's $0.01 gain. Adjusted EBITDA fell 36% to $8 million, with margins shrinking 320 basis points to 5.4%, driven by lower fixed-cost absorption, costs from Automated Stores rework, and inventory reserves.
One thing that stands out is the cautious demand environment, especially in North America, where Sanger Sequencing for Multiomics and core Sample Management products like Automated Stores and Cryogenic Systems saw declines. Adding to the pressure, the company recorded a $149 million non-cash goodwill impairment—$112.4 million in Multiomics and $36.6 million in Sample Management—which pushed GAAP earnings into an operating loss of $165.8 million. I also checked this using Tickeron’s AI Screener to gauge how AZTA stacks up against industry peers on these metrics.
The Revised FY2026 Outlook
Management didn't stop at reporting the miss; they also cut the full-year FY2026 guidance significantly. Total reported revenue is now expected at $603–$621 million, with organic growth adjusted to -2% to +1% from the previous 3–5% range. Sample Management growth is projected at low-single-digits rather than mid-single-digits, while Multiomics faces a mid-single-digit decline. Adjusted EBITDA margins are forecasted to be down 125 basis points to flat, compared to prior expansion expectations. Free cash flow guidance softened to a 10–15% improvement. In my view, this reflects execution gaps and demand caution, leading to leadership changes and a sharper operational focus.
Trading Volume and Market Reaction
Trading volume jumped to 964,691 shares, exceeding the average of about 900,000, which underscores the strong investor reaction to the earnings shortfall. AZTA's drop diverged sharply from broader indices, which closed only modestly lower, and biotech ETFs like IBB and XBI, which experienced smaller declines. The stock broke through key technical support around $23–$24, near its recent moving averages, and approached the 52-week low of $19.87, amplifying downside momentum in the healthcare equipment sector.
Spotlight on Trending AI Robots
In my own research process, I often turn to Tickeron’s Trending AI Robots to identify top-performing AI-driven trading bots suited to current conditions. The platform features hundreds of these bots scanning thousands of tickers across strategies like momentum, mean reversion, and sector plays. The trending section curates the strongest live performers, which has been particularly useful amid volatility such as this biotech sell-off. I find it helps pinpoint automated tools with a real edge for stocks like AZTA and its peers—it's a practical way to incorporate data-backed automation into my strategy.
What's Ahead for AZTA Investors
Looking forward, I'm watching Azenta's ability to improve operational execution, including the Multiomics transformation, leadership enhancements, and cost discipline. The Q3 fiscal 2026 earnings, due in early August, will be a critical test for demand recovery and meeting guidance. Analyst consensus maintains an Outperform rating with an average price target of $35–$41, though some recent cuts signal caution. Sector headwinds like biotech funding pressures and economic sensitivity remain, but opportunities persist in recurring revenues from sample repositories and consumables. Keep an eye on the B Medical Systems divestiture and the extension of the long-range plan to 2029 as additional factors to monitor.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
AZTA's RSI Oscillator sits in oversold zone for 1 day
It is expected that a price bounce should occur soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for AZTA crossed bullishly above the 50-day moving average on April 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AZTA advanced for three days, in of 285 cases, the price rose further within the following month. The odds of a continued upward trend are .
AZTA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 166 cases where AZTA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on May 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AZTA as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for AZTA turned negative on May 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
AZTA moved below its 50-day moving average on May 06, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZTA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.551) is normal, around the industry mean (8.441). P/E Ratio (42.431) is within average values for comparable stocks, (157.618). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.282). Dividend Yield (0.000) settles around the average of (0.021) among similar stocks. P/S Ratio (1.435) is also within normal values, averaging (26.756).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. AZTA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AZTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of automation, vacuum and instrumentation solutions
Industry PharmaceuticalsOther
Advertisement